Advisory Committee Split On Whether FDA Should Draft Nanotech Guidance
This article was originally published in The Tan Sheet
Executive Summary
FDA currently lacks information to draft effective guidance about the development of nanotechnology derived drug applications, according to a majority of FDA's Pharmaceutical Science and Clinical Pharmacology advisory committee